Status:
COMPLETED
A First In Human Study Of PF-00184562 In Healthy Volunteers
Lead Sponsor:
Pfizer
Collaborating Sponsors:
PPD Development, LP
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purposes of this study are: * To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and * To explore the exposure-response relationship of neuropsychometric a...
Eligibility Criteria
Inclusion
- Healthy male or female subjects of non-childbearing potential
Exclusion
- Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, psychiatric, neurologic, active infections, immunological, or allergic disease (including drug allergies and seasonal allergies at time of dosing).
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00150215
Start Date
July 1 2005
End Date
October 1 2005
Last Update
July 25 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Austin, Texas, United States, 78744